Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 38 of 49 for:    Recruiting, Not yet recruiting, Available Studies | kidney disease | NIDDK

MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus (MERMAID-T1D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03945747
Recruitment Status : Recruiting
First Posted : May 10, 2019
Last Update Posted : September 26, 2019
Sponsor:
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of Colorado Denver School of Medicine Barbara Davis Center
Colorado Clinical & Translational Sciences Institute
National Center for Advancing Translational Science (NCATS)
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
In type 1 diabetes (T1DM), automated insulin delivery (AID) systems such as the hybrid closed loop artificial pancreas (HCL AP) combine the use of an insulin pump, continuous blood sugar monitor, and control algorithm to adjust background insulin delivery to improve time in target blood sugar range. Systems such as the predictive low glucose suspend system (PLGS) pause insulin delivery to try and reduce low blood sugars. We aim to complete a pilot study involving recruitment of youth ages 7 to 18 years from the following groups with type 1 diabetes: control participants consisting of youth on either multiple daily insulin injections or conventional insulin pump therapy that plan to continue with their current treatment modality, youth being transitioned to the HCL AP system, and youth being transitioned to the PLGS system. Individuals will be recruited into each of the aforementioned study groups based on their own expressed desire to either continue on MDI/standard insulin pump therapy or transition to either the HCL AP or PLGS systems. The decision to either continue with current therapy or transition therapy will remain entirely up to the participant and their family and will be based on personal preference and insurance coverage for that individual. We will not be randomizing the participants to any given treatment group during this study but rather will be recruiting based on the participant's decision. We would like to complete a physical exam with pubertal staging, collect blood and urine samples to evaluate cardiometabolic and renal markers, and complete a DXA scan to evaluate total lean and fat mass. After 3-6 months of either continuation of current treatment with either multiple daily insulin injections or conventional insulin pump therapy or transitioning to the HCL AP or PLGS systems, we would like to repeat the previously described blood, urine, and imaging tests for comparison. We are interested in examining the impact of the HCL AP and PLGS systems on maintaining blood sugars in target range, insulin sensitivity, and markers of cardiometabolic and renal function. We hypothesize that pauses in insulin delivery, as seen in the setting of automated insulin delivery systems, will result in improvements in insulin sensitivity, cardiometabolic markers, and renal function markers.

Condition or disease Intervention/treatment
Type1 Diabetes Mellitus Diabetes Mellitus, Type 1 Autoimmune Diabetes Juvenile Diabetes Diabetes Mellitus Complication Diabetic Nephropathies Metabolic Disease Diabetic Kidney Disease Diagnostic Test: Blood draw Diagnostic Test: Urine sample collection Diagnostic Test: DXA scan

Detailed Description:

Background: Over 1.25 million Americans have type 1 diabetes mellitus (T1DM), significantly increasing the risk of early death from cardio-renal disease. Per the American Diabetes Association, only 14% of children with T1DM meet glycemic targets [Wood et al. Diabetes Care 2013; 36:2035-37]. This is a severe and pervasive problem, as a child diagnosed with T1DM today is expected to live up to 17 years less than non-diabetic peers. It is established that time outside of goal glycemic target range increases the likelihood of developing micro- and macro-vascular diabetic complications including diabetic kidney disease (DKD) and cardiovascular disease (CVD). However, metabolic risk factors beyond glycemic control including insulin resistance and obesity are also increasingly recognized to contribute to the increased risk of DKD and CVD. Automated insulin delivery (AID) systems such as the hybrid closed loop artificial pancreas (HCL AP) combine use of an insulin pump, continuous glucose monitor (CGM), and a control algorithm to adjust background insulin delivery to improve time in target range. AID systems such as the predictive low glucose suspend (PLGS) system pause insulin delivery to try to reduce hypoglycemia. AID systems are now seeing markedly increased commercial use; however, the long-term effects on insulin sensitivity, body mass index (BMI), cardio-metabolic markers, and kidney function have not yet been studied. Preliminary basic science research suggests that periods of rest from insulin exposure provided by AID systems may have positive effects on DKD and CVD risk. In this proposal we intend to investigate the gap in knowledge between glycemic changes seen with AID systems and the impact on markers of long-term complications.

Specific Aims and Hypotheses:

Specific Aim 1: To examine the effects of the AID systems on glycemic control and insulin sensitivity as compared to traditional insulin pumps and multiple daily injections in youth with T1DM Hypothesis 1.1: Treatment with the AID systems improves glycemic control in youth with T1DM Hypothesis 1.2: Treatment with the AID systems increases insulin sensitivity and decreases insulin requirement in youth with T1DM

Specific Aim 2: To examine the effects of the AID systems on kidney function and metabolic markers as compared to traditional insulin pumps and multiple daily injections in youth with T1DM Hypothesis 2.1: Treatment with the AID systems improves metabolic markers in youth with T1DM Hypothesis 2.2: Treatment with the AID systems improves kidney function in youth with T1DM

Design: This study is a pilot study aimed at recruiting youth ages 7 to 18 years from the following 3 groups with T1DM: control participants on either multiple daily injections or conventional pump therapy, youth being transitioned to a HCL AP system, and youth being transitioned to a PLGS system. Exclusion criteria include non-T1DM, non-insulin blood glucose altering medications, pregnancy, breastfeeding, or a ketogenic diet. We plan to complete a physical exam with pubertal staging, collect information on recent insulin usage and dosages, fasting serum and urine samples, and a DXA scan before the participant transitions to either a HCL AP or a PLGS system, if applicable. Following 3-6 months of treatment we will then collect the identical data as at baseline. Outcome measures include CGM data, total daily insulin dose, time suspended from insulin delivery, height, weight, BMI, waist circumference, hip circumference, blood pressure, HbA1c, c-peptide, total cholesterol, HDL, LDL, triglycerides, adiponectin, and DXA scan to evaluate cardio-metabolic markers and calculate insulin sensitivity, as well as serum creatinine, cystatin c, copeptin, and urine microalbumin to evaluate kidney health and calculate GFR by Zappitelli and FAS equations.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus (MERMAID-T1D)
Actual Study Start Date : August 14, 2019
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Group/Cohort Intervention/treatment
Control group
Individuals continue current treatment regimen with either standard insulin pump therapy or multiple daily insulin injections for the duration of the study.
Diagnostic Test: Blood draw
Participants will undergo a blood collection for hemoglobin A1c, adiponectin, total cholesterol, LDL, HDL, triglycerides, and c-peptide at baseline and follow up in 3-6 months.

Diagnostic Test: Urine sample collection
Participants will undergo urine sample collection for urine microalbumin and urine creatinine at baseline and follow up in 3-6 months.

Diagnostic Test: DXA scan
Participants will undergo a DXA scan for lean and fat mass measurements at baseline and follow up in 3-6 months.

Hybrid closed-loop artificial pancreas system group
Individuals transition from either standard insulin pump therapy or multiple daily injections to a hybrid closed-loop system at the beginning of the study after initial labs and imaging studies are completed.
Diagnostic Test: Blood draw
Participants will undergo a blood collection for hemoglobin A1c, adiponectin, total cholesterol, LDL, HDL, triglycerides, and c-peptide at baseline and follow up in 3-6 months.

Diagnostic Test: Urine sample collection
Participants will undergo urine sample collection for urine microalbumin and urine creatinine at baseline and follow up in 3-6 months.

Diagnostic Test: DXA scan
Participants will undergo a DXA scan for lean and fat mass measurements at baseline and follow up in 3-6 months.

Predictive low glucose suspend system group
Individuals transition from either standard insulin pump therapy or multiple daily injections to a predictive low glucose suspend system at the beginning of the study after initial labs and imaging studies are completed.
Diagnostic Test: Blood draw
Participants will undergo a blood collection for hemoglobin A1c, adiponectin, total cholesterol, LDL, HDL, triglycerides, and c-peptide at baseline and follow up in 3-6 months.

Diagnostic Test: Urine sample collection
Participants will undergo urine sample collection for urine microalbumin and urine creatinine at baseline and follow up in 3-6 months.

Diagnostic Test: DXA scan
Participants will undergo a DXA scan for lean and fat mass measurements at baseline and follow up in 3-6 months.




Primary Outcome Measures :
  1. Change in estimated insulin sensitivity [ Time Frame: 3-6 months ]
    Estimated by calculating the eIS, Pittsburgh eGDR, and SEARCH IS equations


Secondary Outcome Measures :
  1. Change in estimated glomerular filtration rate (GFR) [ Time Frame: 3-6 months ]
    Estimated by calculating the Zappitelli (CysCrEq) and eGFR-FAS (using serum creatinine) equations

  2. Change in body mass index (BMI) [ Time Frame: 3-6 months ]
    Measured by evaluations of height and weight

  3. Change in lipid profile [ Time Frame: 3-6 months ]
    Measured by fasting blood draw for total cholesterol, LDL, HDL, and triglycerides

  4. Change in c-peptide [ Time Frame: 3-6 months ]
    Measured by fasting blood draw for c-peptide level

  5. Change in DXA scan [ Time Frame: 3-6 months ]
    Evaluation of lean and fat mass by DXA scan


Biospecimen Retention:   Samples Without DNA
Urine and blood samples


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   7 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals aged 7-18 years with known type 1 diabetes mellitus who are either planning to continue with standard insulin pump or multiple daily insulin injection therapy OR planning to transition to an automated insulin delivery system such as the hybrid closed-loop artificial pancreas system or the predictive low glucose suspend system.
Criteria

Inclusion Criteria:

  • Age 7-18 years
  • Type 1 diabetes with at least two of the following criteria: diabetes-associated antibody-positivity, rapid conversion to insulin requirement after diagnosis, absent c-peptide, or DKA at diagnosis
  • Currently receiving insulin therapy by multiple daily injections or standard insulin pump therapy

Exclusion Criteria:

  • Non-type 1 diabetes mellitus
  • Pregnant or breastfeeding
  • Receiving treatment with non-insulin glucose-altering medications including oral anti-hyperglycemic medications, steroids, or antipsychotics
  • Following a ketogenic diet

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03945747


Contacts
Layout table for location contacts
Contact: Kalie L Tommerdahl, MD 720-777-5898 Kalie.Tommerdahl@childrenscolorado.org
Contact: Kristen J Nadeau, MD, MS 720-777-2855 Kristen.Nadeau@childrenscolorado.org

Locations
Layout table for location information
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Kalie L Tommerdahl, MD    720-777-5898    Kalie.Tommerdahl@childrenscolorado.org   
Contact: Kristen J Nadeau, MD, MS    720-777-2855    Kristen.Nadeau@childrenscolorado.org   
Sponsors and Collaborators
University of Colorado, Denver
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of Colorado Denver School of Medicine Barbara Davis Center
Colorado Clinical & Translational Sciences Institute
National Center for Advancing Translational Science (NCATS)

Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT03945747     History of Changes
Other Study ID Numbers: 18-1558
UL1TR002535 ( U.S. NIH Grant/Contract )
5T32DK063687-15 ( U.S. NIH Grant/Contract )
First Posted: May 10, 2019    Key Record Dates
Last Update Posted: September 26, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Colorado, Denver:
Automated insulin delivery systems
Insulin sensitivity
Cardiometabolic function
Renal function
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Diabetic Nephropathies
Metabolic Diseases
Glucose Metabolism Disorders
Endocrine System Diseases
Urologic Diseases
Autoimmune Diseases
Immune System Diseases
Diabetes Mellitus
Diabetes Mellitus, Type 1
Diabetes Complications
Insulin
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs